Navigation Links
HUYA Biosciences Establishes Strategic Partnership with Sun Yat-sen University's School of Pharmaceutical Sciences

SAN DIEGO, Aug. 30 /PRNewswire/ -- HUYA Bioscience International, a company at the forefront of globalizing China's biopharmaceutical innovations, today announced a strategic partnership with the School of Pharmaceutical Sciences at Sun Yat-sen University (SYSU).  The collaborative agreement expands HUYA's foothold in Southern China, aiming to accelerate the development of novel drugs arising from the school's research efforts.

The agreement provides HUYA with access to and first review of certain novel therapeutic candidates owned or controlled by SYSU's School of Pharmaceutical Sciences.  Correspondingly, the school gains access to HUYA's expertise in drug development as well as its global network of pharmaceutical partners.

HUYA is one of the first companies to have recognized China's potential to help meet the global needs for new preclinical and clinical stage compounds.  This partnership is one of a series of collaborations that HUYA has established with leading academic and commercial R&D organizations throughout China in order to bring promising new drugs to global markets.  The company has pioneered in-licensing clinical stage compounds from China and is co-developing them concurrently in the U.S. and China with international partners.

The School of Pharmaceutical Sciences at SYSU, a prominent school in southern China, has the top per-capita research funding among China's pharmaceutical colleges and the capabilities to perform cutting-edge research as well as preclinical and clinical studies.  Research results at the school have been recognized internationally and have won numerous national and provincial awards, including China's state funding for Key Projects on Innovative Drug Discovery. These activities have provided rich sources of novel drug candidates.

"The alliance with the School of Pharmaceutical Sciences at SYSU bolsters our collaborative relationships with the school's outstanding faculty and researchers," said Mireille Gingras, Ph.D., President and CEO of HUYA.  "We believe our combined efforts will not only benefit the growth of both organizations, but also yield product opportunities of high potential to meet global medical needs."

"Our school is committed to internationalizing and commercializing the achievements of our research work," remarked Professor Min Huang, Ph.D., Dean of SYSU's School of Pharmaceutical Sciences.  "We are very pleased to join forces with the HUYA team to reach the goals by sharing our respective expertise and co-developing promising compounds."

ABOUT HUYA BIOSCIENCE INTERNATIONALHUYA is the leader in global co-development of pharmaceutical products originating in China. With six offices strategically located in China, the most comprehensive Chinese compound portfolio, and a fast growing number of exclusive agreements with premier Chinese research and development organizations, HUYA has pioneered the most innovative and productive approach to U.S.-China pharmaceutical co-development.  HUYA offers Western pharmaceutical companies efficient access to innovative drug opportunities and reduces complexity in making deals in China.  The company has become a champion of guiding China's biomedical innovations to the worldwide marketplace. HUYA has joint headquarter offices in San Diego, CA, USA and Shanghai, China.  Additional information about the company is available at

ABOUT THE SCHOOL OF PHARMACEUTICAL SCIENCES, SUN YAT-SEN UNIVERSITY The School of Pharmaceutical Sciences, Sun Yat-sen University (SYSU) was established in 2002 as the first school newly formed after the combination of two universities--SYSU and SYSU of Medicinal Sciences.  It thus leverages all the medicinal research resources from both universities.  In order to develop into a national center for innovative drug research, development and evaluation as well as a training base for professionals in pharmacy, the school has been enriching its disciplines, recruiting outstanding teaching and research personnel, strengthening its infrastructure and logistics, and fostering a culture of creativity.  Through these efforts the school has achieved remarkable results including many award-winning projects.  It has also earned a key leading role in building the Southern China Center for Innovative Pharmaceuticals sponsored by the Guangdong Province.  For more information, visit Wang, Ph.D., MBADirector of Corporate DevelopmentHUYA Bioscience International, LLC+1.858.798.8800ywang@huyabio.comChina:Qing (Vicky) Xia, MS, MBAScientific Research ManagerHUYA Bioscience International, LLC+86.21.51323312vxia@huyabio.comMedia Contact:Juliet

SOURCE HUYA Bioscience International
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. InQ Biosciences Appoints John Ryder as Senior Vice President, Sales & Marketing
2. Neurocrine Biosciences Announces Conference Call and Webcast to Report Second Quarter 2010 Financial Results
3. Award Winning Mayo Clinic Scientist Joins Cardio3 BioSciences
4. SeqWrights Partnership with EraGen Biosciences Contributes to FDA Market Clearance Success
5. Signum Biosciences, Inc. Announces Commercial Launch of Arazine™
6. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant Human Stem Cells
7. Sangamo BioSciences Receives Michael J. Fox Foundation Funding to Develop Novel Drug for the Treatment of Parkinsons Disease
8. Regado Biosciences to Present at the 2010 Wells Fargo Healthcare Conference on June 24, 2010 in Boston, Massachusetts
9. -- Neurocrine Announces a Second Corporate Collaboration Within Twenty-Four Hours -- Neurocrine Biosciences Announces a Worldwide Collaboration With Boehringer Ingelheim to Research and Develop GPR119 Agonists for Type II Diabetes
10. Sangamo BioSciences Announces First Quarter 2010 Conference Call and Webcast
11. Neurocrine Biosciences to Present at the Deutsche Bank 35th Annual Health Care Conference
Post Your Comments:
(Date:9/22/2017)... Sept. 22, 2017  As the latest Obamacare repeal ... Bill Cassidy (R-LA) and Lindsey Graham ... the medical device industry is in an odd place. ... the 2.3% excise tax on medical device sales passed ... want covered patients, increased visits and hospital customers with ...
(Date:9/19/2017)... , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing a ... targeted tissues, announced three leadership team developments today:   ... ... ... Veteran medical device executive Josh Stopek , ...
(Date:9/18/2017)... Pa. and KALAMAZOO, Mich. , Sept. 18, ... , and OptiMed Specialty Pharmacy of ... to offer a strategic hub service that expedites and ... sought-after personal spirometer, Spiro PD 2.0, and wellness management ... spirometer is a medical device used to measure lung ...
Breaking Medicine Technology:
(Date:10/12/2017)... , ... October 12, 2017 , ... IsoComforter, Inc. ( ... announced today the introduction of an innovative new design of the shoulder pad. ... you get maximum comfort while controlling your pain while using cold therapy. By utilizing ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... AccentCare, a leader in post-acute health care, have expanded their existing home health ... Home Health. , AccentCare has been operating a joint venture home health company ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... Hair Restoration, has recently contributed a medical article to the newly revamped ... Dr. Mohebi’s article spotlights the hair transplant procedure known as Follicular Unit ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at Children’s National ... 49th Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. ... for Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., ...
(Date:10/12/2017)... Mich. (PRWEB) , ... October 12, 2017 , ... ... has been named one of Michigan’s 2017 Best and Brightest in Wellness® by ... Brightest in Wellness® awards program on Friday, Oct. 20 from 7:30 a.m. to ...
Breaking Medicine News(10 mins):